Despite a huge amount of progress in the hot space CD47, there’s a large space beyond it to explore, according to DEM Biopharma Inc.’s CEO David Donabedian. The new company just raised $70 million to develop therapies targeting don’t eat me, hence DEM, and eat me signals on cancer cells and macrophages.